Glenmark Pharmaceuticals Q2 FY26 Performance Review

Glenmark Pharmaceuticals Ltd. reported a robust Q2 FY26 Net Profit: Surged by 72.4% to ₹610 crore. This profitability was substantially aided by an exceptional income item of ₹1,385 crore. Revenue from Operations: Grew by 76% to ₹6,047 crore. EBITDA: Showcased a sharp increase to ₹2,359 crore, compared to ₹601 crore in the prior-year quarter. Operating Margin: Expanded significantly to 39%, up from 17.5% in Q2 FY25, reflecting the impact of the aforementioned exceptional gain and strong operational leverage. North America: The business expanded by 7.4% YoY, driven by gains in its injectable portfolio and strong traction within the institutional channel. Europe: Revenue grew by 8.5% YoY, supported by the successful execution of recent product launches. Emerging Markets: The segment delivered a stable performance, contributing ₹658 crore to revenue. India Formulations: Domestic revenue was reported lower at ₹1,650 crore. Management has clarified this was due to one-time GST-related adjustments arising from the company's three-tier distribution structure. Despite the temporary impact on reported sales, Glenmark's underlying domestic market performance remains robust. As per IQVIA data for Q2, the company’s secondary sales (sales from distributors to retailers) grew 10.8%, significantly outperforming the Indian Pharmaceutical Market’s (IPM) growth of 6.4%. Management is confident that this was a transient effect and expects reported growth for the India business to normalise from Q3 FY26 onwards as the GST adjustments taper out. Key innovation milestones include the ongoing global expansion of Ryaltris®, the recent UK launch of Winlevi®, and continued regulatory progress across its specialty and oncology portfolios.